{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T01:49:48Z","timestamp":1786499388798,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clim.2022.109091","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T14:04:44Z","timestamp":1659794684000},"page":"109091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience"],"prefix":"10.1016","volume":"242","author":[{"given":"Maria","family":"Infantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Morena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Antonio","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Romanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cimolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Anna Luisa","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tunnera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Cerutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Anr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Veneziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Casprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2022.109091_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2020.05.009","article-title":"IL-6: relevance for immunopathology of SARS-CoV-2","volume":"53","author":"Gubernatorova","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.clim.2022.109091_bb0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.thromres.2020.09.017","article-title":"Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients","volume":"196","author":"Dujardin","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.clim.2022.109091_bb0015","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/jmv.26527","article-title":"Clinical laboratory characteristics in patients with suspected COVID-19: one single-institution experience","volume":"93","author":"Fei","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.clim.2022.109091_bb0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/1744666X.2021.1905526","article-title":"Circulating calprotectin as a biomarker of COVID-19 severity","volume":"17","author":"Mahler","year":"2021","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109091_bb0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/stem.150398","article-title":"Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, Upar","volume":"15","author":"Plesner","year":"1997","journal-title":"Stem Cells"},{"key":"10.1016\/j.clim.2022.109091_bb0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajcp\/102.6.835","article-title":"Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue","volume":"102","author":"Plesner","year":"1994","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clim.2022.109091_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0037-1615847","article-title":"Mechanisms of signaling through urokinase receptor and the cellular response","volume":"82","author":"Koshelnick","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clim.2022.109091_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.clim.2022.109091_bb0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1464-5491.2011.03513.x","article-title":"The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men","volume":"29","author":"Haugaard","year":"2012","journal-title":"Diabet. Med."},{"key":"10.1016\/j.clim.2022.109091_bb0050","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1681\/ASN.2020060829","article-title":"International study of inflammation in COVID-19 soluble urokinase receptor (SuPAR) in COVID-19-related AKI","volume":"31","author":"Azam","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2022.109091_bb0055","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1911481","article-title":"Soluble urokinase receptor and acute kidney injury","volume":"382","author":"Hayek","year":"2020","journal-title":"N. Engl. J. Med. M"},{"key":"10.1016\/j.clim.2022.109091_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.25038","article-title":"Functional autoantibodies against serpin E2 in rheumatoid arthritis","volume":"62","author":"Maciejewska-Rodrigues","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2022.109091_bb0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trsl.2021.02.007","article-title":"Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time","volume":"232","author":"Enocsson","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.clim.2022.109091_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2018.05.016","article-title":"uPA\/uPAR signaling in rheumatoid arthritis: shedding light on its mechanism of action","volume":"134","author":"Dinesh","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.clim.2022.109091_bb0075","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/SHK.0000000000001434","article-title":"The diagnostic and prognostic value of suPAR in patients with sepsis: a systematic review and meta-analysis","volume":"53","author":"Huang","year":"2020","journal-title":"Shock."},{"key":"10.1016\/j.clim.2022.109091_bb0080","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/cc11463","article-title":"Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor","volume":"16","author":"Giamarellos-Bourboulis","year":"2012","journal-title":"Crit. Care"},{"key":"10.1016\/j.clim.2022.109091_bb0085","doi-asserted-by":"crossref","first-page":"474","DOI":"10.14740\/jocmr4579","article-title":"Evaluation of plasma soluble urokinase plasminogen activator receptor levels in patients with COVID-19 and non-COVID-19 pneumonia: an observational cohort study","volume":"13","author":"Velissaris","year":"2021","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.clim.2022.109091_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13054-020-02897-4","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia","volume":"24","author":"Rovina","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.clim.2022.109091_bb0095","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s13054-020-03336-0","article-title":"Plasma levels of the active form of suPAR are associated with COVID-19 severity","volume":"24","author":"Huang","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.clim.2022.109091_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.791716","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19","volume":"8","author":"Enocsson","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.clim.2022.109091_bb0105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/emermed-2020-210380","article-title":"Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study","volume":"38","author":"Arnold","year":"2021","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.clim.2022.109091_bb0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijid.2021.04.026","article-title":"Admission levels of soluble urokinase plasminogen activator receptor (suPAR) are associated with the development of severe complications in hospitalised COVID-19 patients: a prospective cohort study","volume":"107","author":"Oulhaj","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"21","key":"10.1016\/j.clim.2022.109091_bb9099","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.3390\/jcm10214914","article-title":"Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients","volume":"10","author":"Napolitano","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clim.2022.109091_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211034685","article-title":"suPAR cut-offs for risk stratification in patients with symptoms of COVID-19","volume":"16","author":"Altintas","year":"2021","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.clim.2022.109091_bb0120","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.clim.2022.109091_bb0125","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2022.109091_bb0130","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin definition","volume":"307","author":"Ranieri","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2022.109091_bb0135","article-title":"Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: a systematic review and series of meta-analyses","volume":"15","author":"do Nascimento","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2022.109091_bb0140","first-page":"656","article-title":"Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis","volume":"80","author":"Fu","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.clim.2022.109091_bb0145","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fmed.2020.00526","article-title":"Pulmonary and extra-pulmonary clinical manifestations of COVID-19","volume":"7","author":"Johnson","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.clim.2022.109091_bb0150","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20227","article-title":"Recommendations for the admission of patients with COVID-19 to intensive care and intermediate care units (ICUs and IMCUs)","volume":"150","author":"Swiss Society of Intensive Care Medicine","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.clim.2022.109091_bb0155","author":"NICE"},{"key":"10.1016\/j.clim.2022.109091_bb0160","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.5005\/jp-journals-10071-23601","article-title":"Basic critical care for management of COVID-19 patients: position paper of Indian society of critical care medicine, Part-I","volume":"24","author":"Juneja","year":"2020","journal-title":"Indian J. Crit. Care Med."},{"key":"10.1016\/j.clim.2022.109091_bb0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13054-020-02957-9","article-title":"COVID-19 mortality and ICU admission: the Italian experience","volume":"24","author":"Immovilli","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.clim.2022.109091_bb0170","first-page":"1345","article-title":"COVID-19 Lombardy ICU network, risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy, JAMA","volume":"180","author":"Grasselli","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.clim.2022.109091_bb0175","first-page":"723","article-title":"Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens international symposium","volume":"39","author":"Rello","year":"2020","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"10.1016\/j.clim.2022.109091_bb0180","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3343\/alm.2021.41.6.540","article-title":"Biomarkers for prognosis and treatment response in COVID-19 patients","volume":"41","author":"Bivona","year":"2021","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.clim.2022.109091_bb0185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.120.053311","article-title":"Multiple biomarker approach to risk stratification in COVID-19","volume":"143","author":"Smilowitz","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.clim.2022.109091_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2141","article-title":"Interleukin-6 in Covid-19: a systematic review and meta-analysis","volume":"30","author":"Coomes","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.clim.2022.109091_bb0195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/10408363.2020.1770685","article-title":"Biomarkers associated with COVID-19 disease progression","volume":"57","author":"Ponti","year":"2020","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.clim.2022.109091_bb0200","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1515\/cclm-2020-0369","article-title":"Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"58","author":"Henry","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clim.2022.109091_bb0205","article-title":"suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department. 2021 Nov 29;21(1):149.","volume":"16","author":"Santeri","year":"2021","journal-title":"BMC Emerg Med."},{"issue":"3","key":"10.1016\/j.clim.2022.109091_bb0210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/bmm-2021-0669","article-title":"Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients","volume":"16","author":"Padelli","year":"2022","journal-title":"Biomark Med."},{"key":"10.1016\/j.clim.2022.109091_bb0215","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1515\/cclm-2021-0561","article-title":"Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients","volume":"59","author":"Lippi","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clim.2022.109091_bb0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2022.109091_bb0225","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jmv.25819","article-title":"Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"10","author":"Lagunas-Rangel","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.clim.2022.109091_bb0230","article-title":"The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients","volume":"84","author":"Yanga","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2022.109091_bb0235","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/165974","article-title":"Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view","volume":"2013","author":"Schulte","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.clim.2022.109091_bb0240","first-page":"1","article-title":"IL-1 mediates tissue-specific inflammation and severe respiratory failure in COVID-19","volume":"11","author":"Renieris","year":"2022","journal-title":"J. Innate. Immun."},{"key":"10.1016\/j.clim.2022.109091_bb0245","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00003246-198910000-00001","article-title":"Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans","volume":"17","author":"Damas","year":"1989","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.clim.2022.109091_bb0250","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1378\/chest.103.2.565","article-title":"Serum cytokine levels in human septic shock, relation to multiple-system organ failure and mortality","volume":"103","author":"Pinsky","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.clim.2022.109091_bb0255","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-2168.1998.00710.x","article-title":"Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis, Scottish Sepsis Intervention Group","volume":"85","author":"Wakefield","year":"1998","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.clim.2022.109091_bb0260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00024382-200014010-00013","article-title":"Procalcitonin and proinflammatory cytokine interactions in sepsis","volume":"14","author":"Whang","year":"2000","journal-title":"Shock"},{"key":"10.1016\/j.clim.2022.109091_bb0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood.V75.1.40.40","article-title":"Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF","volume":"75","author":"Schindler","year":"1990","journal-title":"Blood"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:06:40Z","timestamp":1761494800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622001723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":54,"alternative-id":["S1521661622001723"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.109091","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.109091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109091"}}